Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer's Disease Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Beverly Hills, California, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Must have a clinical diagnosis of Alzheimer's Disease
Must be at least 50 years of age
Must fluently read and speak English
Must have a reliable caregiver

Exclusion criteria

Has serious health problems other than Alzheimer's Disease
Cannot swallow whole pills
Has had a menstrual period in the last two years
Takes insulin for diabetes
Has taken Aricept, Reminyl, or Exelon in the last 5 weeks

Treatment and study plan

LY451395

Drug

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Important dates

Study start: 2002
Study completion: 2003
First posted: Jan 20, 2003
Registry last updated: Jul 19, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed